m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03573)
Name
ISIS 122986
Status
Investigative
TTD Drug ID
D0N9VK
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
MAPK/ERK kinase kinase 3 (MAP3K3)
Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122986. The Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) has potential in affecting the response of ISIS 122986 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122986. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ISIS 122986 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary MAPK/ERK kinase kinase 3 (MAP3K3) is a therapeutic target for ISIS 122986. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 122986 through regulating the expression of MAPK/ERK kinase kinase 3 (MAP3K3). [1], [2]
References
Ref 1 N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature. 2015 Feb 26;518(7540):560-4. doi: 10.1038/nature14234.
Ref 2 US patent application no. 6,498,035, Antisense modulation of MEKK3 expression.